4.7 Article

Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

期刊

LANCET NEUROLOGY
卷 18, 期 5, 页码 459-480

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(18)30499-X

关键词

-

资金

  1. National Institutes of Health [U01HG010273]
  2. International Centre for Casemix and Clinical Coding, Faculty of Medicine, National University of Malaysia
  3. Department of Health Policy and Management, Faculty of Public Health, Kuwait University
  4. Department of Science and Technology, Government of India, New Delhi, through INSPIRE Faculty scheme
  5. Institute of Medical Research and Medicinal Plant Studies
  6. Public Health Agency of Canada
  7. Alexander von Humboldt Foundation through the Alexander von Humboldt Professor Award - Federal Ministry of Education and Research
  8. Australian Government
  9. Swedish Heart and Lung Foundation
  10. European Union (FEDER funds) [POCI/01/0145/FEDER/007728, POCI/01/0145/FEDER/007265]
  11. National Funds (FCT/MEC, Fundacao para a Ciencia e a Tecnologia and Ministerio da Educacao e Ciencia) [PT2020 UID/MULTI/04378/2013, PT2020UID/QUI/50006/2013]
  12. Australian Research Council [FT3 140100085]
  13. Wellcome Trust [201900]
  14. Institute for Physical Activity and Nutrition (IPAN), Deakin University
  15. High Blood Pressure Research Council of Australia
  16. Office of Research and Innovation at Xiamen University Malaysia
  17. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre
  18. NINDS [U10NS086484]
  19. German Federal Ministry of Education and Research (nutriCARD) [01EA1411A]
  20. National Health and Medical Research Council (NHMRC) of Australia Senior Research Fellowship
  21. NW London NIHR Collaboration for Leadership in Applied Health Research and Care
  22. Danish National Research Foundation
  23. NHMRC [APP1056929]
  24. Sistema Nacional de Investigacion (Panama)
  25. SIREN grant [U54 U54HG007479]
  26. SIBS Genomics grant [R01NS107900]
  27. Egyptian Fulbright Mission Program
  28. Ministry of Education, Science and Technological Development, Republic of Serbia [175087]
  29. Health Data Research UK
  30. National Institutes of Health (NIH) [NIH U01 NS086090]
  31. United States Department of Defense [DoD W81XWH-14-2-0176]
  32. Generalitat Valenciana [PROMETEOII/2015/021]
  33. ISCIIIFEDER [PI17/00719]
  34. NHMRC (Australia) [1042600]
  35. Maurice Wilkins Centre for Biodiscovery
  36. Cancer Society of New Zealand
  37. Health Research Council
  38. Gut Cancer Foundation
  39. University of Auckland
  40. National Natural Science Foundation of China [81773552]
  41. Chinese NSFC International Cooperation and Exchange Program [71661167007]
  42. MRC [MC_U147585819] Funding Source: UKRI

向作者/读者索取更多资源

Background Neurological disorders are increasingly recognised as major causes of death and disability worldwide. The aim of this analysis from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 is to provide the most comprehensive and up-to-date estimates of the global, regional, and national burden from neurological disorders. Methods We estimated prevalence, incidence, deaths, and disability-adjusted life-years (DALYs; the sum of years of life lost [YLLs] and years lived with disability [YLDs]) by age and sex for 15 neurological disorder categories (tetanus, meningitis, encephalitis, stroke, brain and other CNS cancers, traumatic brain injury, spinal cord injury, Alzheimer's disease and other dementias, Parkinson's disease, multiple sclerosis, motor neuron diseases, idiopathic epilepsy, migraine, tension-type headache, and a residual category for other less common neurological disorders) in 195 countries from 1990 to 2016. DisMod-MR 2.1, a Bayesian meta-regression tool, was the main method of estimation of prevalence and incidence, and the Cause of Death Ensemble model (CODEm) was used for mortality estimation. We quantified the contribution of 84 risks and combinations of risk to the disease estimates for the 15 neurological disorder categories using the GBD comparative risk assessment approach. Findings Globally, in 2016, neurological disorders were the leading cause of DALYs (276 million [95% UI 247-308]) and second leading cause of deaths (9.0 million [8.8-9.4]). The absolute number of deaths and DALYs from all neurological disorders combined increased (deaths by 39% [34-44] and DALYs by 15% [9-21]) whereas their age-standardised rates decreased (deaths by 28% [26-30] and DALYs by 27% [24-31]) between 1990 and 2016. The only neurological disorders that had a decrease in rates and absolute numbers of deaths and DALYs were tetanus, meningitis, and encephalitis. The four largest contributors of neurological DALYs were stroke (42.2% [38.6-46.1]), migraine (16.3% [11.7-20.8]), Alzheimer's and other dementias (10.4% [9.0-124]), and meningitis (7.9% [6.6-10.4]). For the combined neurological disorders, age-standardised DALY rates were significantly higher in males than in females (male-to-female ratio 1.12 [1.05-1.20]), but migraine, multiple sclerosis, and tension-type headache were more common and caused more burden in females, with male-to-female ratios of less than 0.7. The 84 risks quantified in GBD explain less than 10% of neurological disorder DALY burdens, except stroke, for which 88.8% (86.5-90.9) of DALYs are attributable to risk factors, and to a lesser extent Alzheimer's disease and other dementias (22.3% [11.8-35.1] of DALYs are risk attributable) and idiopathic epilepsy (14.1% [10.8-17.5] of DALYs are risk attributable). Interpretation Globally, the burden of neurological disorders, as measured by the absolute number of DALYs, continues to increase. As populations are growing and ageing, and the prevalence of major disabling neurological disorders steeply increases with age, governments will face increasing demand for treatment, rehabilitation, and support services for neurological disorders. The scarcity of established modifiable risks for most of the neurological burden demonstrates that new knowledge is required to develop effective prevention and treatment strategies. Copyright (C) The Author(s). Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据